l=Holmium ethylenediaminetetramethylene phosphonic acid (166Ho-EDTMP) is a short-lived p-emitting radionuclide complexed to an aminophosphonate ligand that we have investigated in a canine model as a potential agent for specific marrow ablation before marrow transplantation. After intravenous injections, l@Ho-EDTMP distributed principally to bone and after 24 hours the concentrations of lssHo-EDTMP in bone were more than 200-fold higher than in any other organ. Increasing dosages of lGBHo-EDTMP led to increasingly prolonged and severe myelosuppression, but myeloablation was not achieved. Histologic examination of recovering animals suggested that the spleen may have acted as a ARROW transplantation is an effective and widely M used treatment for a number of marrow-based diseases, including thalassemia, myelodysplasia, multiple myeloma, and acute and chronic leukemia. A major limitation of marrow transplantation is the inability of currently used preparative regimens to eradicate these diseases reliably without causing intolerable nonhematopoietic toxicities. Although hematologic malignancies have steep doseresponse curves to irradiation, it has been difficult to take advantage of this because of the toxicities of systemic irradiation to nonhematopoietic tissues, principally the lungs, liver, and gastrointestinal tract. Therefore, we have undertaken a series of experiments with the goal of delivering radiotherapy specifically to marrow with the hope of achieving improved disease eradication without increased toxicity. One approach to this goal is the use of radiolabeled monoclonal antibodies reactive with lymphohematopoietic tissues. An alternative approach takes advantage of the fact that marrow is contiguous with bone. Thus, by targeting @-emitting radionuclides to bone, a substantial amount of radiation might be delivered to marrow with relative specificity.
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Initial studies were conducted using lS3Samarium ethylenediaminetetramethylene phosphonic acid (lS3Sm-EDTMP) in a canine model.' lS3Sm primarily emits mediumenergy @ particles with 805 (21%), 702 (44%), and 632 (34%) keV energies, and has a half-life of 46.7 hours. It forms stable chelates with phosphonate ligands that, in turn, bind to normal bone, and particularly to osteoblastic lesions. Accordingly, lS3Sm-EDTMP is being actively investigated as palliative treatment for metastatic bone dise a~e . 2 ,~
In our studies, we showed that after intravenous (IV) injection lS3Sm-EDTMP distributes to bone rapidly and specifically, and that high dosages of lS3Sm-EDTMP (> 30 mCi/kg) were tolerated with myelosuppression as the only toxicity observed in dogs.' However, despite the large amounts of lS3Sm-EDTMP administered, spontaneous hematopoietic recovery occurred without marrow transplantation. Further studies suggested that the reason 153Sm-EDTMP was unable to completely ablate hematopoiesis was because the medium-energy p particles were not sufficiently energetic to deliver radiation to all sites of marrow, and some areas, such as those in the midshaft of long bones that are devoid of trabecular bone, were relatively spared.
The studies described here involve a radionuclide 166Hol-mium (166Ho), which has several properties that make it attractive as a marrow ablative agent. Like lS3Sm, 1 6 6 H~ forms stable chelates with EDTMP, but emits @ particles with more than double the maximum energy of 's3Sm (1.85 MeV [51%] and 1.77 MeV [48%] v 0.80 MeV [21%]) and, therefore, more than double the maximum range in tissue (0.87 cm v 0.30 cm). We hypothesized that this increased energy and increased maximum range might allow for more complete marrow ablation. In addition, 1 6 6 H~ has a shorter half-life than ls3Sm (26.9 hours v 46.7 hours). In the setting of marrow transplantation, a shorter half-life is a potential advantage because it would lessen the interval after administration of the radionuclide until marrow can be safely reinfused.4
MATERIALS AND METHODS
Beagles or harriers raised at the Fred Hutchinson Cancer Research Center or bought from commercial kennels were dewormed, vaccinated against distemper, hepatitis, leptospirosis, and parvovirus, and were observed for disease for at least 2 months. The dogs weighed 7.5 to 12 kg, and were 8 to 18 months old at the time of treatment. Research was conducted according to the principles enunciated in the "Guide for Laboratory Animal Facilities and Care" prepared by the National AcadExperimental subjects. Biodistribution of '@Ho-EDTMP was determined by administering 5 to 9 mCi '&Ho-EDTMP IV to normal beagles. Dynamic images were obtained at 30-second intervals for the first 2 hours and repeated at 24 andlor 48 hours. Images were acquired using an ADAC 330 DPS computer and a General Electric 400 AT y camera (Waukesha. Wl). A symmetric, full width-half maximum window was placed about the 80 keV photopeak. A high energy collimator was used to eliminate scatter from the 1.7 and 1.8 MeV y photons emitted by '&Ho. Immediately after the 24-or 48-hour imaging, the animals were killed. Excised tissues were washed with normal saline, blotted, and weighed before counting. The samples were counted using a y scintillation counter
Eiodirtribution.
Long-term retention was estimated by fitting exponential functions to the organ retention data at known time points. Individual organ masses for each dog obtained at autopsy were used to estimate absorbed doses and compared with a standardized reference model of a I-year-old human.
Measurement of hematopoietic suppression. Normal or splenectomized dogs were injected with increasing activities of '&He EDTMP in a leg vein via IV infusion over 15 minutes using an Isomed infusion pump. Starting on the day of infusion, all dogs were placed on oral nonabsorbable antibiotics (polymyxin and neomycin) and IV antibiotics (ampicillin and Amikacin) as previously described.' Complete blood counts including hematocrit. white blood cell (WBC) count, differential, and platelet counts were obtained daily until recovery of counts or death. Blood chemistries were obtained weekly. Jamshidi needle biopsies of marrow were obtained from the humeral head on days 7, 14, 21, and 28 after therapy. Irradiated red blood cell (RBC) and platelet transfusions were administered as needed. Complete autopsies were performed on all animals that died.
Previously splenectomized animals were placed under general anesthesia and had marrow aspirated from both humeri and femora, after which the marrow was processed and stored in 10% dimethylsulfoxide in the vapor phase of liquid nitrogen as previously described.' Animals were allowed to recover at least 2 weeks before being treated with lMHo-EDTMP. From the time of injection of '&Ho-EDTMP and continuing until recovery of counts. animals received supportive care consisting of oral nonabsorbable antibiotics, IV antibiotics, and irradiated RBC and platelet transfusions. Marrow was thawed and infused 5 to 7 days after injection of the l@Ho-EDTMP, the purpose of the delay being to allow for the radionuclide to decay in order to minimize exposure of newly infused marrow to radiation. lS3Sm-EDTMP, the ratios of activity in bone to other tissues were of the same magnitude. The clearance of 16Ho-EDTMP from bone and blood determined by y camera imaging and actual tissue sampling is shown in Fig 2. The rapid clearance from blood represents skeletal uptake and urinary excretion. Once the IfiHo-EDTMP localized to bone, a biologic half-life of 32 hours, similar to the physical half-life of 16Ho (29.6 hours), indicates that a stable bone-'@Ho-EDTMP complex was formed.
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RESULTS
Clearance of lMHo-EDTMP from bone and blood. Radiation dose delivered to marrow and other organs. Time activity measurement data were obtained from y camera images and compared with measurements of radionuclide concentrations in various tissues obtained at autopsy. These data were used to estimate absorbed doses to organs and marrow tissue per millicurie of I@Ho-EDTMP administered. Shown in Table 2 are the doses delivered to separate organs per millicurie of conjugate injected. Bone and the contiguous marrow received more than 100 times the dose delivered to any nontarget organ. An animal administered 240 mCi '%Ho-EDTMP was determined to receive a marrow dose of 14,000 cGy. The organ with the next highest estimated dose was the liver which received 110 cGy, demonstrating the skeletal specificity of this radiopharmaceutical.
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Eight normal animals were administered injections of 16Ho-EDTMP ranging from 7 to 47.5 mCi/kg. With increasing doses of 16Ho-EDTMP, the extent and duration of marrow suppression increased (see Table 3 and Fig 3) . However, all animals eventually recovered normal hematopoietic activity despite a calculated dose of over 20,000 cGy delivered to red marrow at the highest "j6Ho-EDTMP dose infused, 47.5 mCi/kg. Routine Jamshidi needle biopsies from the humoral head of recovering animals showed severe hypoplasia Hematopoietic suppression with lMHo-EDTMP. coincident with recovering peripheral counts, suggesting an alternative site of hematopoietic activity. Two animals that received 15 mCi/kg of '"Ho-EDTMP were killed after 3 weeks for detailed histologic examination. It was found that the spleens were hyperplastic and some areas of splenic extramedullary hematopoiesis were present.
Within 1 to 2 weeks of treatment, animals that received greater than 20 mCi/kg had evidence of marrow stromal damage, with biopsies showing a marked increase in interstitial material with an eosinophil granular appearance. By 4 weeks, moderate to severe marrow fibrosis was found (see Figs 4 and 5). Marrow fibrosis was reversible, and 6 months after administration of '"Ho-EDTMP marrow biopsies of these animals had largely reverted to normal (Figs 4 and 5) .
Efect of splenectomy on hematopoietic suppression with "Ho-EDTMP. Four animals were administered between 20 and 36 mCi/kg '"Ho-EDTMP after having been previously splenectomized. All four animals died before recovery of either WBC or platelet counts, and at autopsy, marrows in all four animals were found to be aplastic (see Fig 6A) . Four additional splenectomized animals were also administered between 20 and 36 mCi/kg '*Ho-EDTMP followed 5 to 7 days later by infusion of 2.7 to 5.0 x loll autologous marrow cells/kg. All four animals recovered normal granulocyte counts between 17 and 25 days after treatment with the radioconjugate. and two of the four recovered normal platelet function and became long-term survivors (see Fig 6B) . A third animal recovered normal granulocyte function and became platelet transfusion independent but died on day 40 of infection. At autopsy, marrow cellularity had recovered to normal. The fourth animal died on day 28, and at autopsy the marrow showed 40% cellularity. 
DISCUSSION
In these experiments we have shown that in dogs the distribution of IMHo-EDTMP after IV injection is similar to that of YSm-EDTMP, with rapid and specific localization to skeletal bone. Also, like P3m-EDTMP. I'Ho-EDTMP was not able to completely ablate hematopoietic function, even at extremely high doses, despite the increased energy of the B particle emissions associated with IMHo. The observation that two animals administered IMHo-EDTMP and killed at 3 weeks had essentially no hematopoietic activity in the marrow space but had some extramedullary hematopoietic activity in the spleen, suggested that the spleen, an organ to which *&Ho-EDTMP does not localize, might serve as a temporary sanctuary for hematopoietic prccursors after "Ho-EDTMP treatment. This view was further supported by the finding that all four splenectomized animals administered IV "Ho-EDTMP without marrow transplant support died of the consequences of marrow supprcssion without recovery of peripheral counts, and at autopsy were found to have aplastic marrows. In contrast, the four splenectomized animals treated with IMHo-EDTMP and autologous marrow transplantation all recovered leukocyte and granulocyte counts, and three of the four also recovered platelet function. While suggestive, these experiments do not conclusively establish the role of the splecn as an extramedullary sanctuary of hematopoiesis. An alternative explanation for the results seen in splenectomized, nontransplanted animals is that without spleens these animals died earlier of infection than nonsplenectomized dogs, and if supported longer than 3 weeks, might have recovered autologous hematopoietic function.
Nonetheless, whether the spleen served as a sanctuary or not, the results of these studies showed that *&Ho-EDTMP can deliver a substantial radiation dose to the marrow space with considerable specificity. These studies have also demonstrated that damage to the marrow microenvironment is probably the dose-limiting toxicity of "j6Ho-EDTMP when used in the context of marrow transplantation. With doses of IMHo-EDTMP greater than 20 mCi/kg, stromal cell damage was regularly seen as early as day 7 after treatment, and by day 28 grade 4 marrow fibrosis developed. Although these results have not been reported previously as a consequence of treatment with aminophosphonic acid conjugates, this outcome is consistent with previous studies of isolated limb irradiation performed more than 3 decades ago by Knospe et a1,8 in which doses of localized radiation greater than 4,000 cGy led to significant fibrotic reactions within the marrow space. In our animals this effect was reversible, and by 6 months marrow biopsies had largely become normal. In this experiment animals were not followed up beyond 1 year from treatment, so possible late effects on marrow function were untested. The studies described here were undertaken with the ultimate goal of developing 166Ho-EDTMP or similar agents as a method to specifically boost the dose of radiation to marrow before marrow transplantation. With the use of daily fractionated external beam total body radiation (TBI) delivered at 7 to 10 cGy/min, the maximum tolerable dose of radiation is between 12 Gy and 15.75 Gy. Two prospective randomized trials, one in acute myelogenous leukemia (AML) in first remission and one in chronic myelogenous leukemia (CML) in chronic phase, comparing cyclophosphamide plus 12 Gy TBI versus cyclophosphamide plus 15.75 Gy TBI have recently been reported.9J0 In both studies the higher TBI dose was associated with a decrease in leukemic recurrence rates, from 35% to 13% in the case AML, and from 35% to 7% in the case of CML. However, the higher-dose TBI regimen did not result in improved survival because of increased extramedullary toxicities. Combining 166Ho-EDTMP with lower-dose TBI might provide a method to take advantage of the steep dose response of hematopoietic malignancies to irradiation without increased extramedullary toxicities. An obvious limitation to this approach is that 166Ho-EDTMP would not add to the radiation dose delivered to extramedullary sites of disease. For some hematologic malignancies that have a major extramedullary component such as acute lymphocytic leukemia, this is more likely a problem, while for others such as myelodysplasia or multiple myeloma (which are largely marrow-based), this may be less important. Clinical trials would be required to determine the extent of this limitation. Given the impressive specificity of 166Ho-EDTMP, and therefore its lack of extramedullary toxicities, an argument can be made in favor of performing such clinical trials. The optimal dose of 166Ho-EDTMP and the best ways of combining it with systemic therapy are yet to be determined.
